The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases

Luc Rochette, Alexandre Meloux, Eve Rigal, Marianne Zeller, Yves Cottin, Catherine Vergely

Open source

DOI
10.1016/j.pharmthera.2017.08.015
Published
2018-02
Container
Pharmacology & Therapeutics
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.pharmthera.2017.08.015,
  title = {The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases},
  author = {Luc Rochette and Alexandre Meloux and Eve Rigal and Marianne Zeller and Yves Cottin and Catherine Vergely},
  year = {2018},
  journal = {Pharmacology \& Therapeutics},
  doi = {10.1016/j.pharmthera.2017.08.015},
  url = {https://doi.org/10.1016/j.pharmthera.2017.08.015}
}

RIS

TY  - JOUR
TI  - The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases
AU  - Luc Rochette
AU  - Alexandre Meloux
AU  - Eve Rigal
AU  - Marianne Zeller
AU  - Yves Cottin
AU  - Catherine Vergely
PY  - 2018
JO  - Pharmacology & Therapeutics
DO  - 10.1016/j.pharmthera.2017.08.015
UR  - https://doi.org/10.1016/j.pharmthera.2017.08.015
ER  - 

APA

Rochette, L., Meloux, A., Rigal, E., Zeller, M., Cottin, Y., & Vergely, C. (2018). The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2017.08.015

Source records